Effect of new quinolone, CP-99,219-27, in curing intraabdominal abscesses in rats

Infectious Diseases in Clinical Practice

Volumn 5, Issue SUPPL. 3, 1996, Pages

  Thadepalli, Haragopal ^a   Reddy, Umapathi ^b   Chuah, See Kean ^b   Thadepalli, Fernando ^b   Malilay, Cicero ^b   Gollapudi, Sastry ^b  

^a KING DREW MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLINDAMYCIN; GENTAMICIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TROVAFLOXACIN;

ABDOMINAL ABSCESS; ABDOMINAL INFECTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; MALE; NONHUMAN; RAT;

EID: 0029778211     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019048-199606001-00008     Document Type: Article

References (4)

1. Neu HC, Chin N. In vitro activity of the new fluoroquinolone CP-99,219. Antimicrob Agents Chemother 1994;38: 2615-22.
2. Sprangler SK, Jacobs MR, Appelbaum PC. Activity of CP-99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, piperacillin-tazobactam against 489 anaerobes. Antimicrob Agents Chemother 1994;38:2471-6.
3. Girard AE, Girard D, Gootz TD, Faiella JA, Cimochowski CR. In vivo efficacy of trovafloxacin, a new quinolone with extended activities against gram-positive pathogens, S. pneumoniae and B. fragilis. Antimicrob Agents Chemother 1995;39:2210-6.
4. Thadepalli H, Gollapudi S, Chuah SK. Therapeutic evaluation of difloxacin (A-56619) and A-56620 for experimentally induced B. fragilis associated intraabdominal abscess. Antimicrob Agents Chemother 1986;30:574-6.